Higher cytoplasmic and nuclear FGFR2 levels are associated with low overall survival (OS) and disease‐free survival (DFS) rates than lower FGFR2 levels.[12] In contrast, FGFR2 amplification does not affect patient survival.[13] Thus, the precise roles of FGFR2 in human breast cancer risk remain to be established. This evidence concerns the gene FGFR2 and breast cancer.